Trial report in Journal of medical Internet research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05325554 (Research on Multi-mode Rehabilitation of Abdominal Tumor Patients With Simultaneous Radiotherapy and Chemotherapy Based on Mobile Medicine.), which is not on this map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Research on Multi-mode Rehabilitation of Abdominal Tumor Patients With Simultaneous Radiotherapy and Chemotherapy Based on Mobile Medicine.
TypeinterventionalSponsorZhongnan HospitalRan2022 to 2024Enrolled100ConditionsConcurrent Chemoradiotherapy, Nutrition；Multimodal RehabilitationArmsMultimodal rehabilitation
3 · Its place in the literature
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
24 authors.
Lei Yang *Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, and Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Donghu Road 169, Wuhan, 430071, China, 86 02767812592.ORCID http://orcid.org/0000-0002-1465-6102
Wenbo Wang *Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, and Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Donghu Road 169, Wuhan, 430071, China, 86 02767812592.ORCID http://orcid.org/0000-0003-2488-9134
Jing Su *Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, and Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Donghu Road 169, Wuhan, 430071, China, 86 02767812592.ORCID http://orcid.org/0009-0007-9636-1714
Han Wu *Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, and Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Donghu Road 169, Wuhan, 430071, China, 86 02767812592.ORCID http://orcid.org/0000-0003-2095-404X
You WangDepartment of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, and Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Donghu Road 169, Wuhan, 430071, China, 86 02767812592.ORCID http://orcid.org/0000-0001-5507-9164
Jing DaiDepartment of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, and Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Donghu Road 169, Wuhan, 430071, China, 86 02767812592.ORCID http://orcid.org/0000-0002-4433-4905
Jin PengDepartment of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, and Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Donghu Road 169, Wuhan, 430071, China, 86 02767812592.ORCID http://orcid.org/0000-0003-0650-6769
Ling XiaDepartment of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, and Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Donghu Road 169, Wuhan, 430071, China, 86 02767812592.ORCID http://orcid.org/0000-0002-2927-1782
Huangang JiangDepartment of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, and Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Donghu Road 169, Wuhan, 430071, China, 86 02767812592.ORCID http://orcid.org/0000-0002-1841-7504
Hui XuDepartment of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, and Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Donghu Road 169, Wuhan, 430071, China, 86 02767812592.ORCID http://orcid.org/0000-0001-8189-2917
Qingyun WangDepartment of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, and Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Donghu Road 169, Wuhan, 430071, China, 86 02767812592.ORCID http://orcid.org/0000-0001-6335-3960
Fengxia ChenDepartment of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, and Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Donghu Road 169, Wuhan, 430071, China, 86 02767812592.ORCID http://orcid.org/0009-0002-4437-7929
Ying ZhangDepartment of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, and Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Donghu Road 169, Wuhan, 430071, China, 86 02767812592.ORCID http://orcid.org/0009-0000-1678-4442
Hanping ShiDepartment of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, China; State Market Regulation, Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, China.ORCID http://orcid.org/0000-0003-4514-8693
Fuxiang ZhouDepartment of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, and Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Donghu Road 169, Wuhan, 430071, China, 86 02767812592.ORCID http://orcid.org/0000-0001-9216-5395
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Background: Concurrent chemoradiotherapy (CCRT) for abdominal cancer frequently induces muscle loss, weight loss, and malnutrition. Objective: This exploratory randomized phase II trial evaluated whether a multidisciplinary, mobile health (mHealth)-based multimodal rehabilitation program could preserve handgrip strength and muscle mass in patients with abdominal cancer undergoing CCRT. Methods: In this prospective, multicenter, randomized, open-label phase II trial (NCT05325554), 111 eligible patients with abdominal malignancies scheduled for CCRT were randomly assigned (1:1) to receive either multidisciplinary mHealth rehabilitation care (MRC; n=57) or standard care (SC; n=54). The MRC program was delivered by a dedicated multidisciplinary team using the AiNST mHealth platform and wearable heart rate monitors. The primary end point was handgrip strength at the end of CCRT (analyzed with analysis of covariance adjusting for baseline). Secondary end points were exploratory and analyzed without multiplicity adjustment; sensitivity analysis using false discovery rate (FDR) correction was performed. Results: Between February 2022 and April 2023, 111 patients were enrolled. Adherence was high (n=93, 83.9% achieved exercise targets). After adjusting for baseline handgrip strength, the MRC group had significantly higher handgrip strength at the end of CCRT than the SC group (adjusted mean difference 4.87 kg, 95% CI 3.36-6.38; Conclusions: In this exploratory phase II trial, a multidisciplinary, mHealth-based multimodal rehabilitation program was associated with better preservation of handgrip strength, muscle mass, and nutritional status, as well as lower rates of certain treatment toxicities, compared with SC. However, definitive conclusions are limited by the open-label design, heterogeneity of tumor types, and short follow-up. Larger, blinded phase III trials are needed to confirm these findings.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Multidisciplinary mHealth Rehabilitation for Patients With Abdominal Cancer Who Are Receiving Chemoradiotherapy: Randomized Phase II Trial. · full record | OpenQuestion